Quoin Prescription drugs CEO Michael Myers acquires $250,000 in shares

Michael Myers, the Chief Government Officer of Quoin Prescription drugs, Ltd. (NASDAQ:QNRX), a micro-cap pharmaceutical firm with a market capitalization of $2.8 million, has just lately elevated his stake within the firm by buying a considerable quantity of shares. In accordance with a latest SEC submitting, Myers bought a complete of 555,556 atypical shares on December 23, at $0.45 per share, amounting to a complete funding of $250,000. The acquisition value represents a major low cost to the inventory’s 52-week excessive of $6.18.

Along with the shares, Myers additionally acquired Sequence F and Sequence G Warrants, every giving him the correct to buy a further 555,556 shares. These transactions had been a part of Quoin Prescription drugs’ public providing, which closed on the identical date. In accordance with InvestingPro knowledge, analysts preserve a bullish outlook on QNRX with value targets starting from $1.50 to $10.00, suggesting vital upside potential. For deeper insights into QNRX’s valuation and development prospects, buyers can entry complete evaluation by way of InvestingPro’s detailed analysis stories.

Following these transactions, Myers holds direct possession of 602,808 shares. The Warrants are exercisable instantly, topic to a useful possession cap, and every represents the correct to purchase one extra American Depositary Share (ADS). Whereas the corporate maintains a wholesome present ratio of three.02 and holds extra cash than debt on its steadiness sheet, InvestingPro evaluation signifies the corporate faces profitability challenges with adverse earnings within the final twelve months.

In different latest information, Quoin Prescription drugs Ltd. has disclosed phrases for a public providing of securities, aiming to generate roughly $6.8 million. The providing contains American Depositary Shares and warrants exercisable in two and 5 years. Maxim Group LLC is the only placement agent for the providing. The corporate plans to make use of the proceeds for common company functions, together with operational bills, analysis and growth, potential acquisitions, and capital expenditures.

Quoin Prescription drugs has additionally been progressing in its medical trials for QRX003, a possible remedy for Netherton Syndrome. The U.S. Meals and Drug Administration has permitted a further medical examine, marking probably the most in depth utility of QRX003 in a medical setting thus far. The corporate has expanded its medical trials to incorporate new websites within the United Kingdom (TADAWUL:4280) and is getting ready to open extra websites in Western Europe.

Moreover, Quoin Prescription drugs has made amendments to shareholder rights and adjusted govt compensation applications. The shareholders permitted compensation applications for CEO Dr. Michael Myers and COO Denise Carter. The corporate additionally disclosed that it has been granted a further 180-day interval by The Nasdaq Inventory Market LLC to fulfill its minimal bid value requirement.

In one other growth, Quoin Prescription drugs has been granted an extension by The Nasdaq Inventory Market LLC to fulfill its minimal bid value requirement. The corporate is actively exploring choices to regain compliance with Nasdaq’s itemizing necessities. These latest developments underscore Quoin Prescription drugs’ dedication to enhancing shareholder worth and addressing the unmet medical wants of uncommon and orphan illnesses.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.